Companies › Takara Bio
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2032.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TBI-1301 NY-ESO-1 directed CAR-T cell therapy | NY-ESO-1 | Phase 3 | Synovial Sarcomas; NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients | Mar 2032 |
| TBI-1401(HF10) Oncolytic herpes simplex virus-1 (HSV-1) | – | Phase 1 | Pancreatic Cancer Stage III | Mar 2035 |
| TBI-1501 anti-CD19 chimeric antigen receptor (CAR)-T cell therapy | CD19 | Phase 1 | Lymphoblastic Leukemia, Acute Adult | Mar 2035 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02869217 | TBI-1301 | Phase 1 | NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients | Oncology | Nov 2026 |
| NCT07174427 | TBI-1301 | Phase 3 | Synovial Sarcomas | Oncology | Mar 2032 |
| NCT03252808 | TBI-1401(HF10) | Phase 1 | Pancreatic Cancer Stage III | Oncology | Mar 2035 |
| NCT03155191 | TBI-1501 | Phase 1 | Lymphoblastic Leukemia, Acute Adult | Oncology | Mar 2035 |
Immatics US Allogene Therapeutics Lyell Immunopharma Tesaro Vyriad
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.